Mostrar el registro sencillo del ítem

dc.contributor.authorDi Pierdomenico, Johnny
dc.contributor.authorGallego-Ortega, Alejandro
dc.contributor.authorNorte-Muñoz, María
dc.contributor.authorVidal-Villegas, Beatriz
dc.contributor.authorBravo, Isaac
dc.contributor.authorBoluda-Ruiz, María
dc.contributor.authorBernal-Garro, Jose Manuel
dc.contributor.authorFernández Bueno, Iván 
dc.contributor.authorPastor Jimeno, José Carlos 
dc.contributor.authorVillegas-Pérez, María Paz
dc.contributor.authorAvilés-Trigueros, Marcelino
dc.contributor.authorde los Ríos, Cristobal
dc.contributor.authorVidal Sanz, Manuel Antón
dc.date.accessioned2024-11-14T12:14:36Z
dc.date.available2024-11-14T12:14:36Z
dc.date.issued2024
dc.identifier.citationFrontiers in Neuroanatomy 2024;18es
dc.identifier.urihttps://uvadoc.uva.es/handle/10324/71464
dc.descriptionProducción Científicaes
dc.description.abstractPurpose: The aim of this study was to investigate, the neuroprotective effects of a new Gramine derivative named: ITH12657, in a model of retinal excitotoxicity induced by intravitreal injection of NMDA. Methods: Adult Sprague Dawley rats received an intravitreal injection of 100 mM NMDA in their left eye and were treated daily with subcutaneous injections of ITH12657 or vehicle. The best dose–response, therapeutic window study, and optimal treatment duration of ITH12657 were studied. Based on the best survival of Brn3a + RGCs obtained from the above-mentioned studies, the protective effects of ITH12657 were studied in vivo (retinal thickness and full-field Electroretinography), and ex vivo by quantifying the surviving population of Brn3a + RGCs, αRGCs and their subtypes α-ONsRGCs, α-ONtRGCs, and α-OFFRGCs. Results: Administration of 10 mg/kg ITH12657, starting 12 h before NMDA injection and dispensed for 3 days, resulted in the best significant protection of Brn3a + RGCs against NMDA-induced excitotoxicity. In vivo, ITH12657- treated rats showed significant preservation of retinal thickness and functional protection against NMDA-induced retinal excitotoxicity. Ex vivo results showed that ITH12657 afforded a significant protection against NMDA-induced excitotoxicity for the populations of Brn3a + RGC, αRGC, and αONs-RGC, but not for the population of αOFF-RGC, while the population of α-ONtRGC was fully resistant to NMDA-induced excitotoxicity. Conclusion: Subcutaneous administration of ITH12657 at 10 mg/kg, initiated 12 h before NMDA-induced retinal injury and continued for 3 days, resulted in the best protection of Brn3a + RGCs, αRGC, and αONs-RGC against excitotoxicity- induced RGC death. The population of αOFF-RGCs was extremely sensitive while α-ONtRGCs were fully resistant to NMDA-induced excitotoxicity.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleEvaluation of the neuroprotective efficacy of the gramine derivative ITH12657 against NMDA-induced excitotoxicity in the rat retinaes
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.doi10.3389/fnana.2024.1335176es
dc.identifier.publicationtitleFrontiers in Neuroanatomyes
dc.identifier.publicationvolume18es
dc.peerreviewedSIes
dc.description.projectPID2019-106498GB-I00 funded by Ministerio de Ciencia, Innovación y Universidades (MCIN)/AEI/ 10.13039/501100 011033 to MV-S and MA-T; (RetiBrain) RED2018-102499-T to MV-S; and by the Instituto de Salud Carlos III (PI19/01724 to CdlR) and co-funded with the European Regional Development Fund (ERDF) within the “Plan Estatal de Investigación Científica y Técnica y de Innovación 2017–2020” (FIS/PI 18–00754) to MV-Pes
dc.identifier.essn1662-5129es
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem